MedTrace Logo

Feasibility and Safety of Allogeneic Adipose Mesenchymal Stem Cells (aMSCs) Delivery Into Kidney Allografts Procured From Deceased Donors With High Kidney Donor Profile Index (KDPI)

NCT04388761 · Status: WITHDRAWN · Phase: PHASE1 · Type: INTERVENTIONAL

Last updated 2023-10-18

No results posted yet for this study

Summary

The purpose of this research is to test an investigational drug called Adipose Mesenchymal Stem Cells (aMSCs) for the treatment of ischemia re-perfusion injury (IRI) in patients that have had a kidney transplant.

Conditions

  • Ischemia Reperfusion Injury

Interventions

DRUG

Allogeneic adipose derived mesenchymal stem cells

Injection of Allogeneic adipose derived mesenchymal stem cells into the Kidney allograft

Sponsors & Collaborators

  • Tambi Jarmi

    lead OTHER

Principal Investigators

  • Tambi Jarmi, MD · Mayo Clinic

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-09-30
Primary Completion
2024-02-29
Completion
2024-02-29
FDA Drug
Yes

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04388761 on ClinicalTrials.gov